Radiation Oncology

ASTRO Journal Club

Journal Club Q&A done in partnership with ASTRO

Questions discussed in this category

How do you incorporate radiation therapy in patients undergoing CAR T-cell therapy for DLBCL?

Would you offer XRT as bridging for all patients with limited pre CAR-T disease or as consolidation for only those with residual PET-avidity on day+30 post CAR-T?

1 Answer available

Is there an optimal salvage radiation dose for relapsed post-CART disease?

1 Answer available

Would you offer bridging radiation before or after leukapheresis?

Are you concerned about cases where radiation has to be started urgently before leukapheresis?

1 Answer available

How soon after CAR T-cell therapy can salvage radiation be delivered?

3 Answers available

Which patients with relapsed/refractory NHL are appropriate for pre-CAR-T bridging radiation therapy?

2 Answers available

Is there an optimal bridging radiation dose for aggressive B-cell NHL undergoing CAR T-cell therapy?

What influences your decision to proceed with palliative vs. definitive, and standard vs. hypofractionation dosing regimens?

2 Answers available

Papers discussed in this category

International journal of radiation oncology, biology, physics, 2019-12-01

Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.

The Lancet. Oncology, 2019-01

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Molecular therapy : the journal of the American Society of Gene Therapy, 2018-11-07

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.

Cancer immunology research, 2019-07

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Br J Haematol, 2020 Mar 5

Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.

Lancet, 2020 Sep 01

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Blood Adv,

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.

Int J Radiat Oncol Biol Phys, 2020 May 22

Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.

The New England journal of medicine, 2017-12-28

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Radiother Oncol, 2021 Dec 7

Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?

Int J Radiat Oncol Biol Phys, 2021 Dec 1

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.

Int J Radiat Oncol Biol Phys, 2022 Dec 20

Don't put the CART before the horse: The role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma.

Transplant Cell Ther, 2022 Dec 30

Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.

Blood advances, 2020 Jul 28

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022 Oct 26

Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma.

Blood advances, 2020 Nov 24

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Haematologica, 2023 Jun 15

Consolidative radiotherapy for residual FDG activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma.

J Hematol Oncol, 2022 Mar 26

Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.

Blood advances, 2022 May 10

Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.

Radiation Oncology

ASTRO Journal Club

Questions discussed in this category

Papers discussed in this category

Related Topics in Radiation Oncology